As per the research report, the Apheresis Market in Latin America was worth USD 0.24 billion in 2022. It is estimated to be growing at a CAGR of 6.9%, to reach USD 0.33 billion by 2027.
The key factors driving the growth of the Latin American apheresis market are increased demand for blood and blood components coupled with the growing rate of blood donations. In addition, the increasing prevalence of leukemia, acute disseminated encephalomyelitis, multiple sclerosis, autoimmune hemolytic anemia, and neonatal cardiac lupus are driving the market's growth during the forecast period. For example, based on results published in the journal Neurology, in 2017, the prevalence of multiple sclerosis was recorded at 365 cases per 100,000, or 915,000 adults. In 2019, the prevalence rate of multiple sclerosis in Brazil was observed at 13.6 per 100,000 inhabitants. At the same time, the prevalence of multiple sclerosis in Mexico was recorded 25 per 100,000 inhabitants.
The prevalence of diseases such as leukemia and autoimmune disorders is increasing in children; further efforts to develop new apheresis treatment methods explicitly designed for children will present potential market opportunities. Adopting therapeutic apheresis in the pediatric population has shown some very successful rates, although providing therapeutic apheresis to children is a technologically difficult task. This is due to fewer recorded results in children since most apheresis therapies are developed from studies and trials in adult patients. The global incidence of acute lymphocytic leukemia ranges from 2.1 to 3.6 cases per 100,000 population per year, while in Mexico, the incidence is over 6 / 100,000 population per year. The incidence of leukemia in Brazil has increased over time and is currently the ninth most common cancer in the region. With a higher proportion of men, it causes 41.8 to 57.6 cases per million inhabitants.
However, the high cost of apheresis devices and therapeutic apheresis procedures, and the installation of the devices are estimated to limit the market growth to some degree. Furthermore, reducing the rate of blood donation due to strict regulations for blood donation will challenge the market in the coming years. Additionally, other factors such as shortage of skilled professionals, lack of awareness, and the complications following apheresis procedure are projected to hamper the growth of the Latin American apheresis market.
This research report on the Latin America Apheresis Market has been segmented and sub-segmented into the following categories:
By End User:
In 2020, Brazil accounted for the majority of the Latin America apheresis market share. Much of this region can be attributed to the higher incidence of leukemia (both in adults and children), advanced diagnosis technologies, a large population, and the growing presence of technologically advanced products in the country. Leukemia is a common pediatric cancer in the region, with around 49 million children under 15 years of age. The incidence rate among children aged 0-14 in Brazil is 54 per million. The presence of skilled doctors and advancing medical facilities are anticipated to present several growth opportunities during the forecast period.
Argentina is expected to lead the Latin American market and become the fastest growing regional market with a CAGR of 5.3% during the forecast period. The increasing burden of various blood-related diseases such as kidney disease, metabolic disease, cancer, and neurological disorders, the improving health care infrastructure, and the high levels of patient awareness are the main factors favoring the market growth in this region. In 2018, health spending represented more than 9.7% of Argentina's gross domestic product, up from 10.50% the previous year. In 2018, Argentina expressed the second-highest health expenditure in GDP among countries in Latin America and the Caribbean.
KEY MARKET PLAYERS:
Companies playing a leading role in the Latin American apheresis market profiled in the report are Asahi Kasei Medical Co., Ltd., Haemonetics Corporation, Terumo BCT, Inc., Fresenius Medical Care, Kawasumi Laboratories Inc., Cerus Corporation, HemaCare Corporation, Kaneka Corporation, B. Braun Melsungen AG, and Nikkiso Co., Ltd., Therakos, Inc., and Medica S.p.A.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com